[
  {
    "ts": "2026-02-19T01:16:29+00:00",
    "headline": "Zoetis Growth Outlook Shifts As Librela Concerns Weigh On Valuation",
    "summary": "Zoetis (NYSE:ZTS) is reporting delayed revenue growth expectations, with management now pointing to 2027 for a clearer inflection. The company is seeing slower uptake and demand challenges for Librela, its key canine arthritis pain therapy. Competitive products and reports of side-effect concerns are weighing on Librela’s traction in the market. Zoetis, a major animal health company focused on medicines, vaccines, and diagnostics for pets and livestock, is now dealing with a tougher setup...",
    "url": "https://finance.yahoo.com/news/zoetis-growth-outlook-shifts-librela-011629905.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5e5ab39e-dffd-33cb-9991-198712e98164",
      "content": {
        "id": "5e5ab39e-dffd-33cb-9991-198712e98164",
        "contentType": "STORY",
        "title": "Zoetis Growth Outlook Shifts As Librela Concerns Weigh On Valuation",
        "description": "",
        "summary": "Zoetis (NYSE:ZTS) is reporting delayed revenue growth expectations, with management now pointing to 2027 for a clearer inflection. The company is seeing slower uptake and demand challenges for Librela, its key canine arthritis pain therapy. Competitive products and reports of side-effect concerns are weighing on Librela’s traction in the market. Zoetis, a major animal health company focused on medicines, vaccines, and diagnostics for pets and livestock, is now dealing with a tougher setup...",
        "pubDate": "2026-02-19T01:16:29Z",
        "displayTime": "2026-02-19T01:16:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/3a10ea4e2d99097fafd252f90cc495f0",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/f0C7t6iQjaUXO6Sb_gR7gg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/3a10ea4e2d99097fafd252f90cc495f0.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xjacLb9JseQC0Y25VVBzKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/3a10ea4e2d99097fafd252f90cc495f0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zoetis-growth-outlook-shifts-librela-011629905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zoetis-growth-outlook-shifts-librela-011629905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ZTS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]